SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Shorting stocks: Broken stocks - Analysis
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Dale Baker who wrote (1917)10/19/1998 11:55:00 AM
From: Q.  Read Replies (2) of 2506
 
re. MCAR, their whole business consists of training physicians to use their proprietary treatment method for urinary incontinence.

I finally found what that method is:

MedCare Technologies has developed a cost effective, non-drug, non-surgical and non-invasive system for the care and treatment of patients suffering from urinary incontinence. MedCare's proprietary treatment protocol does not require FDA approval, is covered by most health insurance plans and results in the reduction or complete elimination of the most commonly found urinary incontinence symptoms. Unlike traditional treatment options, which are costly and often unsuccessful or inadequate, MedCare's treatment program is completely risk free and has a proven success rate in excess of 85% using a multi-modality program based on behavioral techniques and neuromuscular electromyography biofeedback.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News